Potential Gold Rush For Investors Sparked By USA Vs. China Trade War
Right now, China has the US Military in a stranglehold. They hold a monopoly on one of our most CRITICAL defense elements. But thanks to executive orders from both Biden and Trump...
China's Monopoly Is About To Crumble...
Kate Haviland net worth and biography

Kate Haviland Biography and Net Worth

Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. She has served as a member of the board of directors for Fulcrum Therapeutics since June 2018. Kate previously served as Chief Business Officer of Blueprint Medicines from January 2016 to January 2019. Prior to joining Blueprint Medicines, she served as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals. In this role, she oversaw all aspects of the product development strategy for Idera Pharmaceuticals’ rare disease and oncology pipeline programs, including preclinical research, manufacturing and drug supply, regulatory affairs, clinical development and execution and commercial planning. Prior to joining Idera Pharmaceuticals, Kate was Head of Commercial Development at Sarepta Therapeutics, where she was responsible for product development and commercial planning and for cultivating relationships with key opinion leaders and patient advocacy groups. In addition, Kate previously served as Executive Director of Commercial Development at PTC Therapeutics and held corporate development and project management roles at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School.

What is Kate Haviland's net worth?

The estimated net worth of Kate Haviland is at least $4.63 million as of November 3rd, 2022. Ms. Haviland owns 92,281 shares of Blueprint Medicines stock worth more than $4,631,583 as of December 6th. This net worth approximation does not reflect any other assets that Ms. Haviland may own. Learn More about Kate Haviland's net worth.

How do I contact Kate Haviland?

The corporate mailing address for Ms. Haviland and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected] Learn More on Kate Haviland's contact information.

Has Kate Haviland been buying or selling shares of Blueprint Medicines?

During the past quarter, Kate Haviland has bought $48,378.00 of Blueprint Medicines stock. Most recently, on Thursday, November 3rd, Kate Haviland bought 1,100 shares of Blueprint Medicines stock. The stock was acquired at an average cost of $43.98 per share, with a total value of $48,378.00. Following the completion of the transaction, the chief executive officer now directly owns 92,281 shares of the company's stock, valued at $4,058,518.38. Learn More on Kate Haviland's trading history.

Who are Blueprint Medicines' active insiders?

Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Nicholas Lydon (Director), Tracey Mccain (EVP), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.

Are insiders buying or selling shares of Blueprint Medicines?

In the last twelve months, Blueprint Medicines insiders bought shares 2 times. They purchased a total of 6,100 shares worth more than $348,278.00. In the last twelve months, insiders at the biotechnology company sold shares 18 times. They sold a total of 70,732 shares worth more than $5,008,159.86. The most recent insider tranaction occured on November, 3rd when CEO Kate Haviland bought 1,100 shares worth more than $48,378.00. Insiders at Blueprint Medicines own 3.4 % of the company. Learn More about insider trades at Blueprint Medicines.

Information on this page was last updated on 11/3/2022.

Kate Haviland Insider Trading History at Blueprint Medicines

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2022Buy1,100$43.98$48,378.0092,281View SEC Filing Icon  
12/13/2021Sell1,000$98.30$98,300.00View SEC Filing Icon  
6/28/2021Sell1,000$90.24$90,240.0054,948View SEC Filing Icon  
10/16/2020Sell13,334$101.23$1,349,800.8256,172View SEC Filing Icon  
9/22/2020Sell3,143$85.49$268,695.0745,981View SEC Filing Icon  
1/10/2020Sell7,763$85.16$661,097.0823,628View SEC Filing Icon  
8/19/2019Sell95$85.00$8,075.0015,960View SEC Filing Icon  
7/16/2019Sell1,571$95.47$149,983.3717,436View SEC Filing Icon  
6/17/2019Sell11,952$96.46$1,152,889.9212,160View SEC Filing Icon  
3/1/2019Sell21,644$85.05$1,840,822.2020,018View SEC Filing Icon  
2/12/2018Sell6,775$74.93$507,650.7512,649View SEC Filing Icon  
10/5/2017Sell5,449$66.44$362,031.56View SEC Filing Icon  
9/18/2017Sell6,356$60.03$381,550.686,356View SEC Filing Icon  
7/5/2017Sell7,265$54.66$397,104.907,265View SEC Filing Icon  
6/28/2017Sell6,357$50.00$317,850.006,357View SEC Filing Icon  
See Full Table

Kate Haviland Buying and Selling Activity at Blueprint Medicines

This chart shows Kate Haviland's buying and selling at Blueprint Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Blueprint Medicines Company Overview

Blueprint Medicines logo
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $48.55
Low: $48.03
High: $49.93

50 Day Range

MA: $50.45
Low: $41.06
High: $67.91

2 Week Range

Now: $48.55
Low: $40.78
High: $111.78


20,754 shs

Average Volume

562,781 shs

Market Capitalization

$2.90 billion

P/E Ratio


Dividend Yield